Individual treatment response in attention-deficit/hyperactivity disorder: broadening perspectives and improving assessments

被引:0
作者
Hodgkins, Paul [1 ]
Dittmann, Ralf W. [2 ]
Sorooshian, Shaw [3 ]
Banaschewski, Tobias [2 ]
机构
[1] Shire Dev LLC, Global Hlth Econ & Outcomes Res, Wayne, PA 19087 USA
[2] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Dept Child & Adolescent Psychiat & Psychotherapy, Mannheim, Germany
[3] Shire AG, Nyon, Switzerland
关键词
adaptive clinical trial; ADHD; functional impairment; health-related quality of life; individualized medicine; patient-reported outcome; treatment; DEFICIT HYPERACTIVITY DISORDER; QUALITY-OF-LIFE; DRIVING PERFORMANCE; DOUBLE-BLIND; METHYLPHENIDATE TREATMENT; PSYCHIATRIC COMORBIDITY; OROS-METHYLPHENIDATE; YOUNG-ADULTS; CHILDREN; ADHD;
D O I
10.1586/ERN.13.31
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Attention-deficit/hyperactivity disorder (ADHD) is a highly complex disorder with multiple treatment options. Impairments associated with ADHD, rather than symptoms defining the disorder, are the primary reason for referral of individuals to clinical services; consequently, they should also be key targets for intervention. Impairments are moderated by factors such as comorbidities, family environment and intelligence quotient, and particular challenges may vary between patients. The understanding of patient and family treatment preferences, as well as identification of treatment needs and goals, should drive future clinical practice. This review addresses the assessment of ADHD treatment goals and outcomes in clinical practice, and discusses changes in future clinical research studies necessary to progress the utilization of an individualized medicine approach in ADHD.
引用
收藏
页码:425 / 433
页数:9
相关论文
共 65 条
  • [1] [Anonymous], 2005, Primary Psychiatry
  • [2] [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787
  • [3] [Anonymous], GUID IND AD DES CLIN
  • [4] Achieving Remission as a Routine Goal of Pharmacotherapy in Attention-Deficit Hyperactivity Disorder
    Antoni Ramos-Quiroga, J.
    Casas, Miguel
    [J]. CNS DRUGS, 2011, 25 (01) : 17 - 36
  • [5] Advances in understanding and treating ADHD
    Antshel, Kevin M.
    Hargrave, Teresa M.
    Simonescu, Mihai
    Kaul, Prashant
    Hendricks, Kaitlin
    Faraone, Stephen V.
    [J]. BMC MEDICINE, 2011, 9
  • [6] Barkley R.A., 2006, ADHD REPORT, V14, P1, DOI DOI 10.1521/ADHD.2006.14.2.1
  • [7] The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)
    Bernardi, S.
    Faraone, S. V.
    Cortese, S.
    Kerridge, B. T.
    Pallanti, S.
    Wang, S.
    Blanco, C.
    [J]. PSYCHOLOGICAL MEDICINE, 2012, 42 (04) : 875 - 887
  • [8] BIEDERMAN J, 1993, AM J PSYCHIAT, V150, P1792
  • [9] The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: A randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm
    Biederman, Joseph
    Fried, Ronna
    Hammerness, Paul
    Surman, Craig
    Mehler, Bruce
    Petty, Carter R.
    Faraone, Stephen V.
    Miller, Carolyn
    Bourgeois, Michelle
    Meller, Benjamin
    Godfrey, Kathryn M.
    Reimer, Bryan
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2012, 46 (04) : 484 - 491
  • [10] Is Response to OROS-Methylphenidate Treatment Moderated by Treatment with Antidepressants or Psychiatric Comorbidity? A Secondary Analysis from a Large Randomized Double Blind Study of Adults with ADHD
    Biederman, Joseph
    Mick, Eric
    Spencer, Thomas
    Surman, Craig
    Faraone, Stephen V.
    [J]. CNS NEUROSCIENCE & THERAPEUTICS, 2012, 18 (02) : 126 - 132